Development Programs

Infectious Disease

Preclinical

Phase 1

Phase 2

Phase 3

Hepatitis B Prophylaxis

Sci-B-Vac®

VLP

Approved for use and commercially-available in Israel

100%

Phase 3 Complete (US, EU, CAN)

100%

Hepatitis B Therapeutic

VBI-2601

VLP

Phase 1b/2a

55%

Cytomegalovirus Prophylaxis

VBI-1501

eVLP

Phase 1 Complete

52%

Coronavirus Prophylaxis

VBI-2900

eVLP

Preclinical

15%

Zika Virus Prophylaxis

VBI-2501

eVLP

Preclinical

15%

Immuno-Oncology

Preclinical

Phase 1

Phase 2

Phase 3

Glioblastoma

VBI-1901

eVLP

Phase 1/2a

55%

Medulloblastoma

VBI-2701

eVLP

Preclinical

25%